DIAGNOSTIC TOOL FOR MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER

DIAGNOSTIC
Non-invasive test that differentially diagnoses Bipolar Disorder and Major Depressive Disorder in adolescent patients with almost 90 percent accuracy.

TECHNOLOGY TYPE
Imaging
Magnetic Resonance Spectroscopy
Neuroimaging
Bipolar Disorder
Major Depressive Disorder
Software

STAGE OF DEVELOPMENT
- Algorithm developed.
- Additional studies and reimbursement strategy required.

IP PROTECTION
Nationalized PCT Pending
Diagnosis of Affective Disorders Using Magnetic Resonance Spectroscopy Neuroimaging
US20170209084A1

FEATURES AND BENEFITS
- Enables clinicians to rapidly, differentially diagnose MDD or BD using safe, non-invasive measurements
- Facilitates faster delivery of appropriate treatment
- Increases accuracy of initial diagnosis

TECHNOLOGY SUMMARY
Similar presenting symptoms make it difficult to distinguish between Bipolar Disorder (BD) and Major Depressive Disorder (MDD) leading nearly 70 percent of patients to be misdiagnosed initially. Incorrect diagnoses results in delays in appropriate treatment and increased costs to the healthcare system. Adolescents experience higher choline levels in the anterior cingulate cortex when suffering from MDD than BD. Magnetic Resonance Spectroscopy (MRS) provides information regarding the biochemistry of specific regions in the brain. A novel algorithm, developed by researchers at the University of Utah, processes spectroscopic data to provide total choline levels, which can then differentiate between the two diseases. Additional scans can be used to assess efficacy of prescribed treatments for both diseases by comparing current choline levels to the patient’s initial scan and levels of healthy patients.

RECENT PUBLICATIONS

INVENTOR PROFILE
Perry Renshaw, Ph.D., Professor - Psychiatry
Douglas Kondo, M.D., Associate Professor - Psychiatry
Xianfeng Shi, Ph.D., Research Assistant Professor - Psychiatry